Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Jeong Heo et al.|Journal of Clinical Oncology|2013Cited by 775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020Cited by 190
Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity MapChueh‐Chuan Yen, Jonathan A. Fletcher, Li‐Tzong Chen et al.|International Journal of Oncology|2019Cited by 12